HER2 expression, as assessed using immunohistochemistry (IHC) and in situ hybridization (ISH), categorizes breast cancer into HER2-positive (HER2 overexpression) and HER2-negative subtypes [6]. Here, ERBB2 is linked to breast carcinoma.